Tyche Industries Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 2/6
Tyche Industries's earnings have been declining at an average annual rate of -5.4%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 1.1% per year. Tyche Industries's return on equity is 9.7%, and it has net margins of 18%.
Key information
-5.4%
Earnings growth rate
-5.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 1.1% |
| Return on equity | 9.7% |
| Net Margin | 18.0% |
| Next Earnings Update | 14 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Tyche Industries makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 680 | 123 | 98 | 0 |
| 31 Mar 24 | 697 | 122 | 100 | 0 |
| 31 Dec 23 | 808 | 142 | 103 | 0 |
| 30 Sep 23 | 786 | 145 | 99 | 0 |
| 30 Jun 23 | 773 | 137 | 95 | 0 |
| 31 Mar 23 | 756 | 142 | 96 | 0 |
| 31 Dec 22 | 671 | 116 | 92 | 0 |
| 30 Sep 22 | 616 | 89 | 85 | 0 |
| 30 Jun 22 | 660 | 108 | 88 | 0 |
| 31 Mar 22 | 630 | 93 | 85 | 0 |
| 31 Dec 21 | 632 | 89 | 89 | 0 |
| 30 Sep 21 | 725 | 137 | 99 | 0 |
| 30 Jun 21 | 725 | 159 | 89 | 0 |
| 31 Mar 21 | 794 | 200 | 93 | 0 |
| 31 Dec 20 | 776 | 223 | 79 | 0 |
| 30 Sep 20 | 763 | 207 | 73 | 0 |
| 30 Jun 20 | 763 | 205 | 73 | 0 |
| 31 Mar 20 | 743 | 176 | 75 | 0 |
| 31 Dec 19 | 705 | 150 | 79 | 0 |
| 30 Sep 19 | 630 | 118 | 79 | 0 |
| 30 Jun 19 | 582 | 83 | 72 | 0 |
| 31 Mar 19 | 539 | 71 | 72 | 0 |
| 31 Dec 18 | 517 | 65 | 77 | 0 |
| 30 Sep 18 | 498 | 59 | 75 | 0 |
| 30 Jun 18 | 475 | 52 | 78 | 0 |
| 31 Mar 18 | 516 | 59 | 75 | 0 |
| 31 Dec 17 | 542 | 57 | 97 | 0 |
| 30 Sep 17 | 531 | 54 | 98 | 0 |
| 30 Jun 17 | 512 | 47 | 94 | 0 |
| 31 Mar 17 | 439 | 31 | 68 | 0 |
| 31 Dec 16 | 461 | 26 | 103 | 0 |
| 30 Sep 16 | 482 | 18 | 101 | 0 |
| 30 Jun 16 | 464 | 12 | 62 | 0 |
| 31 Mar 16 | 552 | 25 | 102 | 0 |
| 31 Dec 15 | 563 | 45 | 105 | 0 |
| 30 Sep 15 | 557 | 45 | 105 | 0 |
| 30 Jun 15 | 639 | 37 | 64 | 0 |
| 31 Mar 15 | 639 | 19 | 97 | 0 |
| 31 Dec 14 | 581 | 2 | 108 | 0 |
| 30 Sep 14 | 694 | 8 | 106 | 0 |
| 30 Jun 14 | 861 | 31 | 51 | 0 |
| 31 Mar 14 | 1,043 | 55 | 102 | 0 |
| 31 Dec 13 | 1,309 | 77 | 91 | 0 |
Quality Earnings: 532384 has high quality earnings.
Growing Profit Margin: 532384's current net profit margins (18%) are higher than last year (17.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 532384's earnings have declined by 5.4% per year over the past 5 years.
Accelerating Growth: 532384's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 532384 had negative earnings growth (-10.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.4%).
Return on Equity
High ROE: 532384's Return on Equity (9.7%) is considered low.